DXCM DexCom, Inc.

DXCM DexCom, Inc.

Healthcare · Medical Devices

Desk view

Watchingmedium conviction · entry <$65 — not entered
Basis Entry target
Updated

Market read

Scan convergence 2 scans as of 2026-10-16 2 bull converging

POC $72.55 · VWAP $70.74 · +21.6% vs 12m avg buyer

uptrend vol: compressedgaps: overnight-shiftchurn: quiet as of

Insiders quiet 0 buy / 0 sell · Form 4, 90d

Cluster EVP, Director + 1 other sold $1.1M, Sep 14–16

Coverage

DXCM Price Structure

Loading chart…

Loading timeframes…

Peers

Every watchlist DXCM belongs to, members best 30-day change first — DXCM highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.

@healthcare-scan
@healthcare
@biotech-scan

Next earnings DXCM reports in 12 days Oct 29

Last report Jul 30

Reported the quarter ending 2026-06-30: revenue $1.31B, diluted EPS $0.64, net income $249M (SEC filing). Across the print the stock moved +11.1% (close before → first close after).

full note →

Against street estimates

How DXCM's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.

8 most recent of 9 quarters · newest report Jul 30 · projection Oct 16

Result
Jul 30 0.610.70+15.1%Beat
Apr 30 0.470.56+19.0%Beat
Feb 12 0.650.68+4.5%Beat
Oct 30 '25 0.570.61+7.5%Beat
Jul 30 '25 0.440.48+8.3%Beat
May 1 '25 0.330.32-2.6%Miss
Feb 13 '25 0.500.45-9.9%Miss
Oct 24 '24 0.430.45 GAAP ≠ +3.5%Beat
Types
Jul 30 Catalyst DXCM earnings
Jul 29 Catalyst DXCM earnings